Hubbell (NYSE:HUBB) Reports Sales Below Analyst Estimates In Q1 Earnings
Electrical and electronic products company Hubbell (NYSE:HUBB) fell short of the market's revenue expectations in Q1 CY2025, with sales falling 2.4% year on year to $1.37 billion. Its non-GAAP profit of $3.50 per share was 6% below analysts' consensus estimates.
Is now the time to buy Hubbell? Find out in our full research report.
Revenue: $1.37 billion vs analyst estimates of $1.38 billion (2.4% year-on-year decline, 1.3% miss)
Adjusted EPS: $3.50 vs analyst expectations of $3.72 (6% miss)
Adjusted EBITDA: $285.7 million vs analyst estimates of $301.6 million (20.9% margin, 5.3% miss)
Management reiterated its full-year Adjusted EPS guidance of $17.60 at the midpoint
Operating Margin: 17.5%, up from 16.3% in the same quarter last year
Free Cash Flow Margin: 0.8%, down from 3.7% in the same quarter last year
Market Capitalization: $19.46 billion
'Our results in the first quarter were driven by continued strong operating performance in our Electrical Solutions segment and a return to organic growth in Grid Infrastructure, offset by anticipated softness in Grid Automation and the impact of higher cost inflation' said Gerben Bakker, Chairman, President and CEO.
A respected player in the electrical segment, Hubbell (NYSE:HUBB) manufactures electronic products for the construction, industrial, utility, and telecommunications markets.
A company's long-term performance is an indicator of its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Over the last five years, Hubbell grew its sales at a tepid 4.6% compounded annual growth rate. This wasn't a great result compared to the rest of the industrials sector, but there are still things to like about Hubbell.
Long-term growth is the most important, but within industrials, a half-decade historical view may miss new industry trends or demand cycles. Hubbell's annualized revenue growth of 5% over the last two years aligns with its five-year trend, suggesting its demand was consistently weak.
This quarter, Hubbell missed Wall Street's estimates and reported a rather uninspiring 2.4% year-on-year revenue decline, generating $1.37 billion of revenue.
Looking ahead, sell-side analysts expect revenue to grow 6.2% over the next 12 months, similar to its two-year rate. Although this projection indicates its newer products and services will catalyze better top-line performance, it is still below average for the sector. At least the company is tracking well in other measures of financial health.
Software is eating the world and there is virtually no industry left that has been untouched by it. That drives increasing demand for tools helping software developers do their jobs, whether it be monitoring critical cloud infrastructure, integrating audio and video functionality, or ensuring smooth content streaming. Click here to access a free report on our 3 favorite stocks to play this generational megatrend.
Hubbell has been a well-oiled machine over the last five years. It demonstrated elite profitability for an industrials business, boasting an average operating margin of 16.5%.
Looking at the trend in its profitability, Hubbell's operating margin rose by 6.2 percentage points over the last five years, as its sales growth gave it operating leverage.
In Q1, Hubbell generated an operating profit margin of 17.5%, up 1.2 percentage points year on year. The increase was encouraging, and because its operating margin rose more than its gross margin, we can infer it was more efficient with expenses such as marketing, R&D, and administrative overhead.
We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company's growth is profitable.
Hubbell's EPS grew at a spectacular 15.4% compounded annual growth rate over the last five years, higher than its 4.6% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded.
We can take a deeper look into Hubbell's earnings to better understand the drivers of its performance. As we mentioned earlier, Hubbell's operating margin expanded by 6.2 percentage points over the last five years. On top of that, its share count shrank by 1.5%. These are positive signs for shareholders because improving profitability and share buybacks turbocharge EPS growth relative to revenue growth.
Like with revenue, we analyze EPS over a more recent period because it can provide insight into an emerging theme or development for the business.
For Hubbell, its two-year annual EPS growth of 16.6% was higher than its five-year trend. We love it when earnings growth accelerates, especially when it accelerates off an already high base.
In Q1, Hubbell reported EPS at $3.50, down from $3.60 in the same quarter last year. This print missed analysts' estimates, but we care more about long-term EPS growth than short-term movements. Over the next 12 months, Wall Street expects Hubbell's full-year EPS of $16.47 to grow 8.6%.
We struggled to find many positives in these results. Its EBITDA missed significantly and its EPS fell short of Wall Street's estimates. Overall, this quarter could have been better. The stock remained flat at $358.88 immediately after reporting.
The latest quarter from Hubbell's wasn't that good. One earnings report doesn't define a company's quality, though, so let's explore whether the stock is a buy at the current price. What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here, it's free.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
United Healthcare: Earnings, A $200 Billion Overreaction
One of the most dramatic reactions from the Q1 2025 earnings season came from United Healthcare (NYSE:UNH), which shed over $200 billion in market cap and cratered 23% intra-day post-earnings along with continued decline upon the resignation of its CEO and a potential DOJ inquiry. At first glance, that kind of move suggests something catastrophic although the actual results paint a very different picture. Warning! GuruFocus has detected 4 Warning Sign with UNH. The selloff was driven by a 2% increase in Medicare Advantage costs and higher utilization trends (greater related medical expenses), which led to a reduction in 2025 earnings guidance from $29 to $26 per share initially and later with guidance lifted. That's collectively a $3 hit to EPS which is material from initial guidance, but not earth-shattering especially considering UNH is stil projected to have 20.65 billion in 2024 full year net income based on revisions of major investment banks aggregated by Refinitiv along with 25-30 billion for FY26. That level of profit implies a P/E of roughly 12 and a forward P/E of less than 10 (representing a forward cash flow yield of 10%, a truly absurd financial metric for a company of this size), which is deeply discounted for a business of this scale, profitability, and consistency. The increase in utilization is also expected within the earnings call to normalize to historical averages in the near future and this isn't the first time a Medicare Advantage utilization has caused the share price to decline. In June 2023 a similar utilization increase was seen and the effects were short lived, negligible to profitability and the share price quickly was achieving new highs just a six weeks later. Given how the insurance operation works, premiums can also be raised to offset additional care expenses encountered to maintain similar margins and levels of profitability. The CEO also stepped down due to stated personal reasons, while for investors having a CEO step down is typically seen as something negative, the successor for the position is the long term prior CEO Steven J Hemsley, an executive that oversaw exceptional increases in financial operations, efficiency, and stewardship of the company through industry opportunities. While the stock declined rather significantly upon his appointment, this would seem to be dramatic given the prior CEO executed incredible shareholder returns and growth of operations. The last contributor to major negative sentiment is the "announcement/accusation" by journalists a DOJ probe into medicare advantage billing escalating from civil to criminal (uncorroborated by the DOJ or any legal agency), the company explicitly denied any knowledge or informational requests related to such a probe or its supposed existence and given a prior legal ruling in the civil case that there was no apparent incorrect coding for billing, the legitimacy of this seems to be in question. While if the probe is found to be legitimate in the future, as incredible as it sounds, the company would also likely not have any difficulty financing a fine/outlay of significant size. UNH generates profits from a few large business segments albeit diversified due to the massive scale, the insurance operation in which premiums are received and invested/used to pay out claims respectfully and represents the largest health insurer in the US. The other major component of business operations is Optum, which consists of its pharmacy benefit manager operations, Optum Health which directs healthcare directly, and Optum Insights which provides data analytics and consulting. The hit to guidance was within the legacy insurance segment, which remains wildly profitable although the real driver of earnings growth (a greater than 50% share of net income) is seen within Optum which would seem to be unaffected. UNH's capital allocation strategy has historically been a masterclass in shareholder returns. The company has averaged 2-4 billion in quarterly stock buybacks, while simultaneously paying out close to $8 billion in annual dividends all without compromising operations or balance sheet strength. The most recent buyback spike in Q4 2024 was nearly $5 billion, the largest in the past three years. Based on the outlandish profitability of UNH and the businesses clear willingness and ability to reward shareholders, once you throw in the fact that there is a significant discount being placed on the business by the market, it becomes clear this is a sizable overreaction and not reflective of the operations or strength of the company. *historically repurchases accelerate for UNH under market declines This level of profitability and shareholder alignment is rare, and it's even more compelling now that the market has mispriced the stock on short-term guidance noise. The biggest opportunities in investing often come when price temporarily detaches from financial reality and that's exactly what this looks like. With the regime of a current market built on fear and facing macroeconomic struggles, health insurance is generally considered a defensive, non-cyclical industry because demand for healthcare remains relatively stable regardless of economic conditions. People don't stop needing medical care during a recession and if anything, economic stress can drive higher Medicaid enrollment or subsidized marketplace coverage. For insurers like UNH, revenue is largely tied to premiums and government reimbursements, which are contractual or regulated and don't fluctuate with consumer sentiment or discretionary spending trends. Even during downturns, enrollment can remain stable or even grow as individuals shift from employer-sponsored plans to government-backed options. Unlike cyclical sectors like consumer discretionary or industrials, healthcare spending is inelastic and people prioritize it no matter what. Moreover, Medicare Advantage and Medicaid, which are a large part of UNH's book, are government-funded and relatively insulated from short-term economic cycles. As for the broader industry landscape, there are no meaningful moves underway to undercut or dismantle the private health insurance model. The regulatory outlook remains stable, and there are no current legislative pressures that would structurally alter the business model of companies like UNH. Importantly, this volatility in premiums is limited to the UnitedHealthcare segment. Optum UNH's faster-growing, higher margin division which continues to deliver strong performance across health services, pharmacy benefits, and data analytics. Together, this structure gives UNH a diversified revenue model that can weather temporary shocks in one segment without compromising overall earnings power and represents a significantly undervalued equity at current market prices. * TipRanks. (n.d.). UnitedHealth (NYSE:UNH) stock buybacks. Retrieved May 3, 2025, from This article first appeared on GuruFocus.
Yahoo
2 hours ago
- Yahoo
Jim Cramer Recommends Royal Caribbean Cruises Over Viking Holding (VIK)
We recently published a list of . In this article, we are going to take a look at where Viking Holdings Ltd (NYSE:VIK) stands against other stocks that Jim Cramer discusses. A caller asked for Cramer's thoughts on Viking Holdings Ltd (NYSE:VIK), and he replied: 'Okay, I like Viking, but I thought they were tepid when they came on, and therefore I'm going to send you to Royal. I think RCL is now the gold standard, and that's the one I want to own.' Viking (NYSE:VIK) provides transport services for travelers and offers tourism experiences that include guided tours and other activities for its guests. Moreover, on March 14, Cramer was bullish on the company as he said: 'Regular viewers know I am a big fan of the cruise lines… Viking's a unique player with an impressive focus on rich American baby boomers. We watched with glee as Viking stock glided higher and higher and higher throughout last year and even the first few weeks of 2025, eventually it peaked at 53 bucks and change in early February just before the market-wide sell-off. Since then, the stock's fallen back to $40, down roughly 25% from its highs just over a month ago… The cruise lines are different from other travel plays. They represent incredible value versus traditional vacation alternatives…For Viking in particular, we have a fresher company-specific catalyst. On Tuesday morning, the company reported an excellent quarter with in-line revenue and impressive 9-cent earnings beat off a 36-cent basis… Overall, VIK ranks 5th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of VIK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
2 hours ago
- Yahoo
Jim Cramer Calls Capital One Financial (COF) a 'Tremendous' Buy
We recently published a list of . In this article, we are going to take a look at where Capital One Financial Corporation's (NYSE:COF) stands against other stocks that Jim Cramer discusses. Talking about deregulation, Cramer noted that Capital One Financial Corporation's (NYSE:COF) merger with Discover Financial Services was possible under the new administration. 'There are many reasons why Trump won in November, inflation, immigration, cultural backlash, but there's one reason why the business community got behind him in a way they never really did in 2016 or 2020, and that's deregulation…[Referring to the Fed's decision to remove Wells Fargo asset cap restriction] This one comes on the heels of the decision by the administration to let Capital One merge with Discover Financial, okay. A smiling face of a customer as they make a deposit at this company's branch. Capital One Financial (NYSE:COF) provides a range of banking and lending products, including credit cards, loans, deposit accounts, and online banking services, while also offering advisory and treasury management solutions. Overall, COF ranks 14th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of COF as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data